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Currently, ceftriaxone is the last remaining drug recommended for empirical 
treatment of gonorrhoea. Neisseria gonorrhoeae with reduced susceptibility to 
ceftriaxone have been isolated worldwide in countries such as Japan, France, 
Spain, Slovenia, Australia and Sweden. These have led to treatment failures and 
the emergence of ceftriaxone-resistant N. gonorrhoeae. Various mutations in 
penA (mosaic and nonmosaic), which encodes the penicillin-binding protein 2 
(PBP2), have been reported to be the primary reason for reduced ceftriaxone 
susceptibility, but it can be reduced further by mutations in mtrR, porBIB and ponA. 
In this study, we aimed to determine the antimicrobial resistance patterns of New 
Zealand isolates of N. gonorrhoeae with reduced susceptibility to ceftriaxone and 
to characterise the penA, mtrR, porBIB and ponA in the isolates.  
 
Methods 
A total of 28 N. gonorrhoeae isolates with elevated ceftriaxone MIC (0.03 to 0.12 
mg/L), collected from 2012 to 2015 and  obtained from the Institute of 
Environmental Science and Research (ESR), were examined in this study. 
Samples came from laboratories in Auckland (26), Wellington (1) and Taranaki 
(1). The antimicrobial resistance of penicillin G, tetracycline, ciprofloxacin, 
azithromycin and ceftriaxone were determined through antimicrobial 
susceptibility test, using minimum inhibitory concentration (MIC) test strips. 
Polymerase chain reactions (PCRs) and sequencing to identify specific mutations 
in penA, mtrR, porBIB and ponA, that are associated with elevated minimum 
inhibitory concentrations (MICs) to ceftriaxone, were undertaken. The association 
between the phenotypic and genotypic results was investigated by comparing the 





Based on the AST results using MIC test strips and interpreted using The 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria, 
23 out of 28 isolates (82%) showed reduced susceptibility to ceftriaxone, with 
MICs of 0.03 to 0.06 mg/L. All of the isolates were resistant to ciprofloxacin, while 
36%, 25% and 7% were resistant to penicillin G, tetracycline and azithromycin, 
respectively. Two azithromycin-resistant N. gonorrhoeae isolates were observed, 
and isolate 264 (azithromycin MIC: 4mg/L) also exhibited reduced susceptibility 
to ceftriaxone (MIC: 0.03 mg/L).  A total of 21% (6/28) of the isolates produced β-
lactamase. The 23 isolates that conveyed reduced ceftriaxone susceptibility were 
found to harbour three or four mutated genes (penA, mtrR and/or porBIB and 
ponA). Reduced susceptibility to ceftriaxone among N. gonorrhoeae isolates in 
this study was associated with mosaic PBP2 (encoded by penA) with 
G545S/A501V mutations, with nonmosaic PBP2 with an A501V mutation, plus 
the presence of mutation in mtrR promoter with G120 and A121 alterations in 
PorBIB. A total of 65% (15/23) of the N. gonorrhoeae isolates with reduced 
susceptibility to ceftriaxone harboured mosaic PBP2 XXXIV, a pattern found in 
N. gonorrhoeae associated with ceftriaxone treatment failures in Europe and 
Australia. The current study also revealed that the partial sequences of four 
mosaic PBP2 (M-2, M-3, M-4, M-5) were different from the common mosaic PBP2 
sequences reported in various studies.  
 
Conclusion 
There is an association between the phenotypic and genotypic character of N. 
gonorrhoeae isolates expressing reduced susceptibility to ceftriaxone in this 
study population. Furthermore, the presence of important mosaic PBP2 that link 
to ceftriaxone treatment failure might be circulating among N. gonorrhoeae 
isolates in New Zealand . 
 






Alhamdulillah, all praises to Allah S.W.T and to Him alone for the strengths and 
His blessings in completing this thesis. 
I would like to express the deepest gratitude to my main supervisor Dr. Mary 
Nulsen for her full support, expert guidance, understanding, and encouragement 
throughout my stay in New Zealand, my study and research. Without her 
incredible patience and timely wisdom and counsel, my thesis work would not be 
successful. In addition, I express my deepest appreciation to Dr. Jackie Benschop 
and Dr. Julie Collins-Emerson for the support, passion in this project and having 
served on my committee. Their thoughtful questions and comments were valued 
greatly.  
I would also like to thank Dr. Kristene Gedye for her hard work, valuable advice 
and dedication that makes this project successful. I am so grateful to have you 
on the team.  
To New Zealand Aid programme, I express thanks from deep within my heart and 
show my gratitude for granting me the New Zealand Aid Commonwealth 
Scholarship. I sincerely thank you for providing me the chance to pursue my 
postgraduate studies.  
Special thanks go to my numerous beloved friends for the never ending support 
and encouragement and make my life in New Zealand is one of the amazing 
experience. You know who you are. 
Finally, I would like to thank my parents, brothers and sisters, the rest of my 
families, and friends back home for their unconditional love and support during 
the last two years. I would not have been able to complete this thesis without their 






Table of Contents 
 
List of Tables…………………………………………………………………………………………….ix 
List of Figures …………………………………………………………………………………………xiv 
Abbreviations …………………………………………………………………………………………xvii 
Nucleotides abbreviations …………………………………………………………………………….xix 
Amino acid abbreviations …………………………………………………………………………….xx 
 
1. CHAPTER ONE : INTRODUCTION ...................................................................................... 2 
1.1. Gonorrhoea: Epidemiology and Health Impact ............................................................. 3 
1.2. Neisseria gonorrhoeae morphology and traits .............................................................. 5 
1.3. Methods to diagnose gonorrhoea ................................................................................. 7 
1.4. Chronology of multidrug-resistant (MDR) Neisseria gonorrhoeae .............................. 14 
1.5. Extended-spectrum cephalosporins (ESCs), the current treatment for gonorrhoea, and 
the emergence of N. gonorrhoeae with reduced susceptibility to ESCs ................................. 21 
1.6. Chromosomal gene mutations in penA, mtrR, porBIB and ponA cause reduced 
susceptibility to ESCs .............................................................................................................. 24 
1.6.1. Penicillin-binding protein 2 (penA) gene ............................................................. 29 
1.6.2. The role of mosaic penA (PBP2) in causing reduced susceptibility to ESCs ..... 30 
1.6.3. Significant involvement of mosaic PBP2 (I312M, V316T and G545S alterations)
 33 
1.6.1. Other PBP2 alterations and their role in reduced susceptibility to ESCs ........... 35 
1.7. Introduction to the multiple transferable resistance (mtr) locus .................................. 42 
1.7.1. Mutations in the mtrR cause N. gonorrhoeae to become resistant to hydrophobic 
agents, penicillin and azithromycin ...................................................................................... 43 
1.7.2. Mutations in the mtrR region enhanced the reduced susceptibility to ceftriaxone in 
N. gonorrhoeae .................................................................................................................... 45 
1.8. Introduction to penB and porBIB .................................................................................. 47 
1.8.1. The alterations of loop 3 area of PorB (porBIB) ................................................... 48 




1.9. Introduction to ponA .................................................................................................... 52 
1.9.1. Mutation in ponA which causes N. gonorrhoeae to become resistant to ESCs. 54 
1.10. Treatment failure of infections due to N. gonorrhoeae with reduced susceptibility to 
ceftriaxone ............................................................................................................................... 55 
1.11. Susceptibility of New Zealand isolates of N. gonorrhoeae to ceftriaxone ................... 60 
 
2. CHAPTER TWO: METHODS AND MATERIALS ............................................................... 63 
2.1. Ethical Approval .......................................................................................................... 63 
2.2. Isolates ........................................................................................................................ 63 
2.2.1. Specimen culture................................................................................................. 65 
2.2.2. Specimen storage ............................................................................................... 66 
2.2.3. Reference isolates............................................................................................... 66 
2.3. Phenotypic Characterisation ....................................................................................... 68 
2.3.1. β-lactamase production (nitrocefin test) .............................................................. 68 
2.3.2. Antimicrobial susceptibility test (Etest) ................................................................ 68 
2.3.3. Comparison of two Etest brands: Liofilchem s.r.l (Italy) and bioMérieux (Solna, 
Sweden)……. ....................................................................................................................... 72 
2.3.4. Determination of the effect of using different media to culture N. gonorrhoeae prior 
to Etest on the MIC result .................................................................................................... 72 
2.3.5. Statistical analysis ............................................................................................... 73 
2.4. Polymerase Chain Reaction (PCR) for mosaic penA, penA, mtrR, porBIB and ponA . 74 
2.4.1. DNA extraction .................................................................................................... 74 
2.4.2. DNA concentration and purity ............................................................................. 74 
2.4.3. Primers for N. gonorrhoeae mosaic penA, mtrR, porBIB and ponA PCR ............ 75 
2.4.4. N. gonorrhoeae PCR protocol development ....................................................... 77 
2.4.5. Preparing the gel and visualising the PCR product ............................................ 81 
2.5. Sequencing ................................................................................................................. 81 
2.5.1. Preparation of DNA template for sequencing ..................................................... 81 





3. CHAPTER THREE: RESULT .............................................................................................. 84 
3.1. Phenotypic Result of N. gonorrhoeae isolates ............................................................ 84 
3.1.1. Comparison between MIC results of ceftriaxone from ESR, Liofilchem Etest strips 
and bioMérieux Etest strips ................................................................................................. 84 
3.1.2. Comparison between MICs of penicillin G determined by Liofilchem Etest strips 
and bioMérieux Etest strips ................................................................................................. 86 
3.1.3. Antimicrobial susceptibility testing (AST) result of penicillin G, tetracycline, 
ciprofloxacin, azithromycin and ceftriaxone of N. gonorrhoeae with reduced susceptibility to 
ceftriaxone ........................................................................................................................... 86 
3.1.4. Antimicrobial susceptibility testing (AST) result comparison between European 
Committee of Antimicrobial Susceptibility Testing (EUCAST) Guideline and Clinical & 
Laboratory Standards Institute (CLSI) guideline .................................................................. 93 
3.1.5. Effect of using GC II agar, chocolate supplemented agar, and GC saponin agar 
prior to Etest for penicillin G and ceftriaxone Etest result .................................................... 98 
3.1.6. Comparison of ceftriaxone MIC of isolate 963 and WHO K control strain incubated 
with 3% CO2 and 5% CO2 .................................................................................................... 99 
3.2. PenA (PBP2) analysis of N. gonorrhoeae isolates ................................................... 100 
3.2.1. Mosaic penA PCR and sequencing .................................................................. 100 
3.2.2. Mosaic penA in N. gonorrhoeae isolates .......................................................... 102 
3.2.3. Comparison of mosaic penA (PBP2) of N. gonorrhoeae isolates  with various 
published penA (PBP2) sequence ..................................................................................... 107 
3.2.4. Confirmation of nonmosaic penA for six N. gonorrhoeae isolates that were 
negative for mosaic penA PCR .......................................................................................... 112 
3.2.5. Identification of various PBP2 alterations in part D PBP2 (residues 430 to 555) 
associated with elevated MIC of ceftriaxone ..................................................................... 115 
3.2.6. The overall pattern of PBP2 in N. gonorrhoeae isolates ................................... 118 
3.2.7. Association of different PBP2 patterns with MIC of ceftriaxone of N. gonorrhoeae 
isolates in New Zealand ..................................................................................................... 122 
3.2.8. Analysis of full length of penA of WHO K, WHO L, ATCC 49226 and strain 1380
 …………………………………………………………………………………………126 
3.3. MtrR analysis of N. gonorrhoeae isolates ................................................................. 132 
3.3.1. MtrR PCR and sequencing ............................................................................... 132 
3.3.2. Identification of adenine (A) deletion in mtrR promoter, G45D in the MtrR coding 
region, and other alterations in MtrR protein ..................................................................... 133 
vii 
 
3.3.3. Association of alterations in mtrR promoter and MtrR coding region with 
susceptibility level of ceftriaxone ....................................................................................... 137 
3.4. PorBIB analysis of N. gonorrhoeae isolates ............................................................... 139 
3.4.1. PorBIB amplification & sequencing .................................................................... 139 
3.4.2. PorBIB alterations and association ceftriaxone susceptibility of N. gonorrhoeae 
isolates …………………………………………………………………………………………141 
3.5. PonA analysis of N. gonorrhoeae isolates ................................................................ 141 
3.5.1. PonA amplification and sequencing .................................................................. 147 
3.5.2. Identification of L421P alteration in PBP1 and the association with susceptibility 
level of ceftriaxone. ............................................................................................................ 148 
3.6. Association of various combination of mutated penA, mtrR, porBIB and ponA with 
susceptibility level of ceftriaxone ........................................................................................... 150 
 
4. CHAPTER FOUR: DISCUSSION ...................................................................................... 160 
4.1. Effect of Media and Etest strips on MIC results ........................................................ 160 
4.2. Antimicrobial resistance in N. gonorrhoeae .............................................................. 162 
4.3. N. gonorrhoeae DNA leaching using elution buffer (10mM TrisHCl, pH 8.0) ........... 166 
4.4. Association of mosaic PBP2 alterations in N. gonorrhoeae isolates with reduced 
susceptibility to ceftriaxone.................................................................................................... 167 
4.5. Association of nonmosaic PBP2 alterations in N. gonorrhoeae isolates with reduced 
susceptibility to ceftriaxone.................................................................................................... 170 
4.6. Association of mtrR alterations in N. gonorrhoeae isolates with reduced susceptibility 
to ceftriaxone ......................................................................................................................... 173 
4.7. Association of G120 and A121 alterations of PorBIB with N. gonorrhoeae isolates with 
reduced susceptibility to ceftriaxone ..................................................................................... 175 
4.8. Association of ponA (L421P) mutation with decreased susceptibility of ceftriaxone in N. 
gonorrhoeae in New Zealand ................................................................................................ 177 
4.9. Combinations of mutated penA, mtrR, porBIB and ponA as markers to identify N. 
gonorrhoeae with reduced susceptibility to ceftriaxone ........................................................ 178 
 
5. CHAPTER FIVE: CONCLUSION ...................................................................................... 181 
 
6. REFERENCES .................................................................................................................. 185 
viii 
 
7. APPENDIX ......................................................................................................................... 212 
7.1. APPENDIX A: Massey University Human Ethics Committee (MUHEC) application 212 
7.2. APPENDIX B: The Hawkes Bay Medical Research Foundation (HBMRF) Funding 213 
7.3. APPENDIX C: School of Food Nutrition, Massey University Funding ...................... 214 
7.4. APPENDIX D: Institute of Veterinary, Animal and Biomedical Sciences (IVABS) 
Funding .................................................................................................................................. 215 
7.5. APPENDIX E: Methods and Materials ...................................................................... 216 
7.6. APPENDIX F: Phenotypic Testing ............................................................................ 222 
7.7. APPENDIX G: PenA (PBP2) analysis ....................................................................... 234 
7.8. APPENDIX H: MtrR analysis ..................................................................................... 251 





















LIST OF TABLES 
 
 
CHAPTER ONE: INTRODUCTION 
Table 1-1 Classification of antibiotics used to treat N. gonorrhoeae. ......................................... 15 
Table 1-2 The development antimicrobial resistance in N. gonorrhoeae ................................... 16 
Table 1-3 Stepwise transformation of N. gonorrhoeae FA19 strains with mosaic penA, mtrR, 
porBIB and ponA of N. gonorrhoeae 35/02 (adapted from Zhao et al. (2009)) ........................... 25 
Table 1-4 Susceptibility to ceftriaxone and mutated penA, mtrR, porBIB and ponA observed in N. 
gonorrhoeae in published journals .............................................................................................. 28 
Table 1-5 Verified mutations within PBP2 that contribute the decreased susceptibility to 
ceftriaxone  .................................................................................................................................. 38 
Table 1-6 Mutations within the mtrR region that contribute to the decreased susceptibility to 
hydrophobic agents, penicillin and ceftriaxone ........................................................................... 45 
Table 1-7 Published PorBIB mutations that contribute to reduced susceptibility to ESCs (e.g. 
ceftibuten, cefpodoxime, cefuroxime, cefotaxime, and ceftriaxone) ........................................... 51 
Table 1-8 Published ceftriaxone-resistant N. gonorrhoeae strains, and N. gonorrhoeae isolates 
with reduced susceptibility to ceftriaxone associate with ceftriaxone treatment failures ............ 58 
Table 1-9 N. gonorrhoeae with reduced susceptibility to ceftriaxone in New Zealand and the 
presence of mosaic penA ............................................................................................................ 60 
 
CHAPTER TWO: METHODS AND MATERIALS 
Table 2-1 List of Neisseria gonorrhoeae isolates from the Institute of Environmental Science and 
Research Limited (ESR) and N. gonorrhoeae control strains ..................................................... 64 
Table 2-2 Antimicrobial range and minimum inhibitory concentration (MIC) data for WHO 
reference strain panel and CLSI reference strain: ATCC 49226 ................................................ 67 
Table 2-3 MIC interpretative Standard according to The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) ................................................................................................ 70 
Table 2-4 Comparison of MIC results for penicillin G and ceftriaxone between Liofilchem MIC test 
strips and bioMérieux Etest ......................................................................................................... 72 
Table 2-5 A test to compare the MIC results of penicillin G and ceftriaxone between Liofilchem 
MIC test strips and bioMérieux Etest .......................................................................................... 73 
Table 2-6 List of primers used for mosaic penA, penA, mtrR, porBIB and ponA PCR ................ 76 
Table 2-7 Optimised PCR conditions for amplification of set A, set B, set C and set D of penA 78 
Table 2-8 PCR master mix for amplification of set A, set B, set C and set D of penA ............... 78 
Table 2-9 PCR conditions for amplification of the mtrR gene ..................................................... 79 
Table 2-10 PCR master mix used for amplification of the mtrR gene......................................... 79 
Table 2-11 PCR conditions for amplification of the ponA gene .................................................. 80 
Table 2-12 PCR master mix used for amplification of the ponA gene ........................................ 80 
x 
 
CHAPTER THREE: RESULTS 
Table 3-1 MIC of ceftriaxone and penicillin for N. gonorrhoeae isolates and control strains ..... 88 
Table 3-2 MICs of tetracycline, ciprofloxacin, azithromycin, and nitrocefin results for N. 
gonorrhoeae isolates and control strains .................................................................................... 90 
Table 3-3 Antibiotic susceptibility of N. gonorrhoeae isolates based on The European Committee 
of Antimicrobial Susceptibility Testing (EUCAST) guidelines ..................................................... 92 
Table 3-4 Comparison of antibiotic susceptibility of N. gonorrhoeae isolates using EUCAST and 
CLSI guideline ............................................................................................................................. 95 
Table 3-5 Optimised PCR conditions for mosaic penA (Protocol 2) ......................................... 100 
Table 3-6 Optimised PCR master mix for mosaic penA PCR (Protocol 2) ............................... 101 
Table 3-7 Mosaic penA PCR for N. gonorrhoeae isolates ........................................................ 103 
Table 3-8 Summary of mosaic penA PCR results for N. gonorrhoeae isolates ........................ 104 
Table 3-9 Nucleotides comparison between mosaic penA of N. gonorrhoeae isolates with NG-3 
and LM306 strain ...................................................................................................................... 110 
Table 3-10 Amino acid changes detected in the mosaic PBP2 sequence of N. gonorrhoeae 
isolates (consensus sequence) compared to wild type N. gonorrhoeae LM306 ...................... 111 
Table 3-11 Amino acid differences between the consensus mosaic PBP2 sequence of N. 
gonorrhoeae isolates and with NG-3 and LM306 strain ........................................................... 111 
Table 3-12 Amino acid variation detected in part B of PBP2 (residues 183 to 347)  for N. 
gonorrhoeae isolates that were negative for mosaic penA ....................................................... 114 
Table 3-13 Summary of PBP2 patterns in N. gonorrhoeae isolates ......................................... 120 
Table 3-14 Comparison of PBP2 sequence observed in N. gonorrhoeae isolates with published 
mosaic PBP2 sequences in N. gonorrhoeae isolates ............................................................... 121 
Table 3-15 PBP2 patterns observed in N. gonorrhoeae isolates.............................................. 123 
Table 3-16 Summary of ceftriaxone susceptibility and different types of alterations in PBP2 of N. 
gonorrhoeae isolates used in the study .................................................................................... 124 
Table 3-17 Amino acid alterations of PBP2 of WHO K,  NG-3 N. gonorhoeae strain, WHO L, 
ATCC 49226 and 1380 isolate .................................................................................................. 130 
Table 3-18 Alterations in mtrR promoter and MtrR coding region of N. gonorrhoeae isolates . 136 
Table 3-19  Summary of alterations in mtrR promoter and MtrR coding region of N. gonorrhoeae 
isolates ...................................................................................................................................... 138 
Table 3-20 PCR conditions for amplification of the porBIB gene of N. gonorrhoeae (protocol 4)
 .................................................................................................................................................. 139 
Table 3-21 Optimised PCR master mix for porBIB PCR (protocol 4) ........................................ 140 
Table 3-22 G120 and A121 PorBIB alterations of N. gonorrhoeae isolates ............................. 145 
Table 3-23 PorBIB alterations in N. gonorrhoeae isolates ........................................................ 146 
Table 3-24 PonA (PBP1) alteration in N. gonorrhoeae isolates ............................................... 150 
Table 3-25 Summary of mutations penA, mtrR, porBIB and ponA that are associated with elevated 
ceftriaxone MIC in N. gonorrhoeae with reduced susceptibility to ceftriaxone ......................... 152 
xi 
 
Table 3-26 Susceptibility to ceftriaxone, and key alterations identified in PBP1, PBP2, MtrR and 
PorBIB in N. gonorrhoeae isolates ............................................................................................ 153 
Table 3-27 Association of mutated penA, mtrR, porBIB and ponA with N. gonorrhoeae isolates
 .................................................................................................................................................. 156 
Table 3-28 Association of mutated penA, mtrR, porBIB and ponA with ceftriaxone MIC level of N. 
gonorrhoeae isolates ................................................................................................................. 157 
 
APPENDIX E 
Table E1 Storage of N. gonorrhoeae isolates in BHI + 20% glycerol broth .............................. 217 
Table E2 Preparation of 1L of 1X Phosphate Buffered Saline (PBS) ....................................... 218 
Table E3 Preparation of 20% Chelex® 100 suspensions for DNA extraction ............................ 218 
Table E4 DNA purity and concentration measurement using Nanodrop ND-1000 spectrophotometer
 .................................................................................................................................................. 219 
Table E5 Preparation of working solution for primers (10μM) .................................................... 220 
Table E6 Preparation of working solution dNTPs (10mM) (Promega NZ) .................................. 220 
Table E7 Preparation of 1% agarose gel with safranin O ......................................................... 220 
Table E8 Published control sequence used to identify variations in amino acid sequences in each 
resistance gene ......................................................................................................................... 221 
 
APPENDIX F 
Table F1 Estimated fold difference in dilution (log2) between Liofilchem s.r.l (Italy) and bioMérieux 
(Sweden) for ceftriaxone (CRO) and penicillin G ...................................................................... 223 
Table F2 Susceptibility classification of penicillin G and ceftriaxone for 21 N. gonorrhoeae isolates 
using Liofilchem and bioMérieux .............................................................................................. 224 
Table F3 MIC results agreement between Liofilchem and bioMérieux Etest strips of N. 
gonorrhoeae isolates plus WHO K, WHO L, WHO F and ATCC 49226 ................................... 225 
Table F4 Estimated fold difference in dilution (log2) between ceftriaxone MIC test result from the 
current study and the Institute of Environmental Science and Research (ESR)……………….226 
Table F5 Agreement between MIC of ceftriaxone of the current study and result from ESR ... 228 
Table F6 Association of β-lactamase expression with susceptibility level of penicillin G ......... 229 
Table F7 MIC results of penicillin G where isolates were grown on GC II agar, GC saponin agar 
and chocolate supplemented agar prior to MIC test ................................................................. 230 
Table F8 MIC results of ceftriaxone where isolates were grown on GC II agar, GC saponin agar 
and chocolate supplemented agar prior to MIC test ................................................................. 231 
Table F9 Evaluation of the use of GC saponin agar and chocolate supplemented agar to grow N. 
gonorrhoeae prior to Etest for penicillin G and ceftriaxone ....................................................... 232 
Table F10 Evaluation of the used of GC II agar and chocolate supplemented agar to grow N. 
gonorrhoeae prior to Etest for penicillin G and ceftriaxone ....................................................... 233 
xii 
 
Table F11 Ceftriaxone MIC (mg/L), colony forming unit (CFU) and colony morphologies of strain 
963 incubated in candle jar and car carbon dioxide (CO2) incubator …………………….234 
APPENDIX G 
Table G1 Mosaic penA PCR method development (Protocol 1 and Protocol 3) ...................... 235 
Table G2 Master Mix for mosaic penA PCR (Protocol 1 and Protocol 3) ................................. 236 
Table G3 Fragment migration and estimated size of N. gonorrhoeae mosaic penA PCR product
 .................................................................................................................................................. 237 
Table G4 Amino acid differences between mosaic PBP2 (residues 276 to 329) of 22 N. 
gonorrhoeae isolates and other Neisseria species ................................................................... 240 
Table G5 Comparison of PBP2 alterations in consensus sequence with N. perflava/sicca, N. 
cinerea and N. polysacchareae ................................................................................................ 241 
Table G6 Summary of amino acid alterations in part D of PBP2 sequence of N. gonorrhoeae 
isolates with reduced susceptibility to ceftriaxone .................................................................... 242 
Table G7 Summary of PBP2 alterations of N. gonorrhoeae isolates with reduced susceptibility to 
ceftriaxone ................................................................................................................................. 243 
Table G8 Comparison of part D PBP2 (residues 430 to 560) of mosaic sequences M-1, M-2, M-
3, M-4 and M-5 with mosaic PBP2 pattern XXXIV and wildtype PBP2 of N. gonorrhoeae LM306
 .................................................................................................................................................. 248 
Table G9 Susceptibility to ceftriaxone and PBP2 alterations in N. gonorrhoeae isolates ........ 249 
 
APPENDIX H 
Table H1 Types of alterations observed in mtrR promoter and MtrR coding region of N. 
gonorrhoeae isolates with reduced susceptibility to ceftriaxone ............................................... 252 
 
APPENDIX I 
Table I1 PorBIB PCR protocol development .............................................................................. 253 
Table I2 Summary of various amino acid alterations in PorBIB protein sequence of N. 
gonorrhoeae isolates ................................................................................................................. 254 
 
STORED IN DVD 
Table I Summary of sequencing results OF mosaic penA amplicons from N. gonorrhoeae isolates 
and WHO K control 
Table II Summary of sequencing result for part B penA (nonmosaic confirmation) amplicons for 
nonmosaic N. gonorrhoeae isolates and ATCC 49226 control strain 
xiii 
 
Table III Summary of sequencing result for part D of penA (reverse sequence) amplicons for N. 
gonorrhoeae isolates, WHO K and WHO L control strains 
Table IV Summary of sequencing result for full length of penA (forward sequence) amplicons for 
WHO K, WHO L, ATCC 49226 and isolate 1380 
Table V Summary of sequencing results for mtrR amplicons from 28 N. gonorrhoeae isolates and 
WHO K control 
Table VI Summary of sequencing results for porBIB amplicons 757 bp products for N. gonorrhoeae 
isolates and WHO K control strain 
Table VII Summary of sequencing results for ponA amplicons for N. gonorrhoeae isolates and 
























LIST OF FIGURES 
 
CHAPTER ONE: INTRODUCTION 
Figure 1-1 Alignment of published mosaic PBP2 patterns X, XXXV and XXXVIII, XXXIV and XXXII 
with the wild-type sequence of N. gonorrhoeae LM306. ............................................................. 32 
Figure 1-2 PBP2 structure consists of a dimerisation domain (residues 71 to 221) and a 
transpeptidase domain (residues 263 to 557) [adapted from Ameyama et al. (2002), Ito et al. 
(2004), Osaka et al. (2008) ......................................................................................................... 37 
Figure 1-3 Organisation of the mtrCDE region in gonococci, adapted from Kayla et al. (1995, 
1997), Veal et al. (1998) and Warner et al. (2008).. ................................................................... 43 
Figure 1-4 Amino acid sequences from PorBIB of N. gonorrhoeae strains adapted from Gill et al. 
(1998) and Olesky et al. (2002). ................................................................................................. 51 
Figure 1-5 Organisation of ponA in gonococci, adapted from Ropp and Nicholas (1997), and Ropp 
et al. (2001).. ............................................................................................................................... 53 
Figure 3-1Penicillin G MIC distributions with EUCAST and CLSI guidelines ............................. 96 
Figure 3-2 Tetracycline MIC distributions with EUCAST and CLSI guidelines ........................... 96 
Figure 3-3 Azithromycin MIC distributions with EUCAST and CDC breakpoints established for 
GISP ............................................................................................................................................ 97 
Figure 3-4 Gel electrophoresis of mosaic penA amplicons from DNA extracted from N. 
gonorrhoeae isolates.. ............................................................................................................... 101 
Figure 3-5 Alignment of mosaic penA of N. gonorrhoeae isolates and WHO K control (from 843 
bp to 972 bp). ............................................................................................................................ 105 
Figure 3-6 Comparison of consensus sequence for mosaic penA amplicons (843 bp to 977 bp) 
with wildtype N. gonorrhoeae LM306 and N. gonorrhoeae NG-3.. ........................................... 109 
Figure 3-7 Comparison of the mosaic PBP2 sequence (residues 276 to 329) of N. gonorrhoeae 
isolates with the PBP2 sequence of wildtype N. gonorrhoeae LM306. .................................... 110 
Figure 3-8 Alignment of part B of PBP sequence (residues 183 to 347) of six N. gonorrhoeae 
isolates that were negative for mosaic penA (consensus sequence), ATCC 49226 strain and N. 
gonorrhoeae NG-3 .................................................................................................................... 113 
Figure 3-9 Alignment of part D of PBP2 sequence (residues 430 to 520 ) of N. gonorrhoeae 
isolates, WHO K and WHO L control isolates, with wild-type N. gonorrhoeae LM306. ............ 116 
Figure 3-10 Ceftriaxone MIC distribution between isolates of N. gonorrhoeae with mosaic PBP2 
or nonmosaic PBP2 .................................................................................................................. 125 
Figure 3-11 Gel electrophoresis of full length of penA PCR products amplified from DNA extracted 
from N. gonorrhoeae WHO K, WHO L, ATCC 49226 control strain, and NZ isolate 1380.. ..... 126 
Figure 3-12 Alignment of PBP2 sequence (residues 1 to 390) of 1380, ATCC 49226, WHO L and 
WHO K, with N. gonorrhoeae LM306 and NG-3 strain. The numbering of the sequence is based 
on the sequence of N. gonorrhoeae LM306.. ........................................................................... 128 
xv 
 
Figure 3-13 Gel electrophoresis of mtrR PCR products from DNA extracted from N. gonorrhoeae 
isolates.. .................................................................................................................................... 132 
Figure 3-14 Alignment of partial mtrR sequences (1 to 130 bp residues) of N. gonorrhoeae 
isolates, published mtrR of N. gonorrhoeae (GenBank accession no.: Z25796.1), WHO K and 
WHO F control with 13 bp inverted repeat mtrR promoter sequence ....................................... 134 
Figure 3-15 Alignment of MtrR protein sequences (1 to 130 residues) of N. gonorrhoeae isolates 
with published MtrR protein sequence of N. gonorrhoeae (protein ID: CAA81045.1), positive 
control WHO K and wildtype WHO F. ....................................................................................... 135 
Figure 3-16 Gel electrophoresis of porBIB PCR products consists of four protocols, amplified from 
DNA extracted from N. gonorrhoeae isolates WHOK, ATCC 49226, isolate 729 and 824.. .... 140 
Figure 3-17 Alignment of partial PorBIB amino acid sequence (81 to 210 residues) of N. 
gonorrhoeae isolates, published wild-type PorBIB sequence of N. gonorrhoeae H1-2 (Genbank 
Protein ID: CAA06234.1) and WHO K control strain ................................................................ 143 
Figure 3-18 Gel electrophoresis of the ponA PCR products amplified from DNA extracted from N. 
gonorrhoeae isolates. ................................................................................................................ 147 
Figure 3-19 Alignment PBP1 amino acid sequence (residues 361 to 650) of N. gonorrhoeae 
isolates, the published wild-type PBP1 sequence of N. gonorrhoeae NG00085 (GenBank 
accession no.: AB727713.1, Protein ID: BAM21172.1) and the WHO K control strain ............ 149 
Figure 3-20 Effect of different groups of gene mutations on the susceptibility of ceftriaxone .. 158 
 
APPENDIX G 
Figure G1 Gel electrophoresis of mosaic penA amplicons (Protocol 1). .................................. 235 
Figure G2 Gel electrophoresis of mosaic penA amplicons (Protocol 3) ................................... 236 
Figure G3 Standard curve for migration of mosaic penA PCR product .................................... 237 
Figure G4 Comparison of the mosaic PBP2 amino acid sequence of N. gonorrhoeae isolates with 
the PBP2 sequence of wildtype N. gonorrhoeae strain LM306 and published PBP2 sequences..
 .................................................................................................................................................. 238 
Figure G5 Comparison of the mosaic PBP2 sequence of N. gonorrhoeae isolates with the PBP2 
sequences of other Neisseria species. ..................................................................................... 239 
Figure G6 Comparison of partial mosaic PBP2 M-1, M-2, M-3, M-4 and M-5 with mosaic PBP2 X 
and XXXIV ................................................................................................................................. 241 
Figure G7 Comparison of part D PBP2 of mosaic PBP2 pattern M-1, M-2, M-3, M-4 and M-5 with 
mosaic PBP2 pattern XXXIV and N. gonorrhoeae LM306 strain.............................................. 242 
 
STORED IN DVD 
Figure I Alignment of the part B penA nucleotide sequence of six nonmosaic N. gonorrhoeae 
isolates, ATCC 49226 strain and N. gonorrhoeae NG-3 
xvi 
 
Figure II Alignment of part D penA sequence of 28 N. gonorrhoeae isolates, WHO K, WHO L, and 
N. gonorrhoeae LM306  
Figure III Alignment of penA nucleotide sequence of WHO L, ATCC 49226, 1380 and WHO K 
strain, with N. gonorrhoeae LM306 and NG-3 strain. The numbering of the sequence is based on 
N. gonorrhoeae LM306 
Figure IV Alignment of mtrR sequences of N. gonorrhoeae isolates, mtrR sequence of published 
N. gonorrhoeae, WHO K and WHO F control strain  
Figure V Alignment of partial porBIB nucleotide sequence of N. gonorrhoeae isolates with 
published wild-type porBIB sequence of N. gonorrhoeae HI-2 and WHO K control strain using 
Multalin  
Figure VI Alignment of partial ponA nucleotide sequences of N. gonorrhoeae isolates, published 




















AMR Antimicrobial resistance 
AST Antimicrobial susceptibility testing 
ATCC American type culture collection 
BHI Brain Heart Infusion 
BLAST Basic Local Alignment Search Tool 
CDC Centers for Disease Control and Prevention 
CFU Colony forming unit 
CLSI Clinical Laboratory Standards Institute 
CMRNG Chromosomally-mediated resistant Neisseria gonorrhoeae 
CO2 Carbon dioxide 
CRO Ceftriaxone 
DDBJ DNA Data Bank of Japan 
DHB District health board 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
ESCs Extended-Spectrum Cephalosporins 
ESR Institute of Environmental Science and Research  
EtBr Ethidium Bromide 
EUCAST The European Committee on Antimicrobial Testing 
FDA Food and Drug Administration 
GISP Gonococcal Isolate Surveillance Project  
HIV Human Immunodeficiency Virus  
HLR High-level resistance 
HTH Helix-turn-helix 
IM Intramuscular injection 
MDR Multidrug-resistant 
MgCl2 Magnesium Chloride 
MGS Massey Genome Service 
MIC Minimum Inhibitory Concentration 
MLST Multi-locus sequence typing 
xviii 
 
MSM Men who have sex with men 
mtr Multiple transferable system 
MUHEC Massey University Human Ethics Committee 
NAAT Nucleic Acid Amplification Test 
NCBI National Center for Biotechnology Information 
NETs Neutrophil Extracellular Traps 
NG-MAST Neisseria gonorrhoeae Multi-antigen Sequence Typing 
NPV Negative predictive value 
NZSHS The New Zealand Sexual Health Society Incorporation 
PBP Penicillin Binding Protein 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PEN Penicillin 
PHE Public Health England 
PID Pelvic Inflammatory Disease 
PMNs Polymorphonuclear leukocytes 
PPNG Penicillinase-producing Neisseria gonorrhoeae 
PPV Positive predictive value  
qPCR Quantitative Polymerase Chain Reaction 
STIs Sexually transmitted infections  
TMP-SMX Trimethoprim/sulfamethoxazole 
TAE Tris-Acetate-EDTA 
TrisHCL Tris hydrochloride 
TRNG Tetracycline-resistant Neisseria gonorrhoeae 
WHO World Health Organization 


















A  Adenine 
G  Guanine 
C  Cytosine 
U  Uracil 



















Amino Acids Abbreviations 
 
A  Alanine 
R  Arginine 
N  Asparagine 
D  Aspartic Acid 
C  Cysteine 
E  Glutamic Acid 
Q  Glutamine 
G  Glycine 
H  Histidine 
I  Isoleucine 
L  Leucine 
K  Lysine 
M  Methionine 
F  Phenylalanine 
P  Proline 
T  Threonine 
V  Valine 
Y  Tyrosine 
S  Serine 
W  Tryptophan 
 
 
 
